Dr. Chen is an associate researcher and master's supervisor recruited by Hundred-Talent Program of Sun Yat-sen University. He received his Ph.D. in the University of Oklahoma Health Science Center and worked as a postdoctoral researcher in Moores Cancer Center, UC San Diego. He has published multiple research papers in top journals including Leukemia, Oncogene, and Journal of Hematology and Oncology. His research focuses on precision medicine of hematopoietic malignancies and tyrosine kinase inhibitors.
Working Experience:
3/2018-present: Associate Researcher. The Seventh Affiliated Hospital of Sun Yat-sen University.
8/2015-3/2018: Postdoc employee. Moores Cancer Center. UC San Diego.
Education:
8/2010 – 7/2015 Ph.D. Department of Pathology, The University of Oklahoma Health Science Center.
9/2008 – 7/2010 MS Graduate student, majoring in molecular biology and biochemistry, College of Life Sciences, Jilin University.
9/2004 – 9/2008 Bachelor of Science in Biotechnology, College of Life Sciences, Jilin University.
Research focuses:
1. Targeted therapies in hematopoietic malignancies
2. Development of small molecule targeted drugs
3. Development of therapeutic monoclonal antibodies
4. Molecular diagnosis in hematopoietic malignancies
Publications:
1. Chen Y, Guo Y, Zhao, Ho WT, Fu X, and Zhao ZJ. Identification of an orally available compound with potent and broad FLT3 inhibition activity. Oncogene.2015 Sep 28. doi: 10.1038/onc.2015.362.
2. Yu J*,Chen Y*,Chen L, Zhang L, Rassenti LZ, Widhopf GF, Kipps TJ. Cirmtuzumab Inhibits Ibrutinib-resistant, Wnt5a-induced Rac1 Activation and Proliferation in Mantle Cell Lymphoma. Oncotarget. 2018 May 15;9(37):24731-24736.
3. Chen Y, Pan Y, Guo Y, Zhao W, Ho WT, Wang J, Xu M, Yang FC, Zhao ZJ.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Investig. 2017 Jun 2;4:48.
4. Choi MY, Widhopf GF 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 1;22(6):951-959.e3. doi: 10.1016/j.stem.2018.05.018.
5. Chen Y, Guo Y, Han J, Ho WT, Li S, Fu X, Zhao ZJ. Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity. Journal of Hematology & Oncology 2012 5:39.
6. Guo Y*, Chen Y*, Xu X, Fu X, Zhao ZJ. SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. Journal of Hematology & Oncology 2012 5:72.
7. Yu J, Chen L, Chen Y, Hasan MK, Ghia EM, Zhang L, Wu R, Rassenti LZ, Widhopf GF, Shen Z, Briggs SP, Kipps TJ. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Leukemia. 2017 May 3. doi: 10.1038/leu.2017.132.
8. Hu X, Chen Y, Zhao ZJ: Structure, regulation, and function of TET family proteins. Epigenetic Gene Expression and Regulation (Chapter 17).
9. Shi K, Zhao W, Chen Y, Ho WT, Yang P,Zhao ZJ.Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. Journal of Hematology & Oncology2014 7:25.
10. Yu J, Chen L, Cui B, Wu C, Choi MY, Chen Y, Zhang L, Rassenti LZ, Widhopf GF, Kipps TJ.Cirmtuzumab inhibits Wnt5a-induced Rac1-activation in chronic lymphocytic leukemia treated with ibrutinib.Leukemia.2016 Dec 1. doi: 10.1038/leu.2016.368.
Email: cheny653@mail.sysu.edu.cn